The iNSiGHT DXA system is a cutting-edge in vivo Dual Energy X-Ray Absorptiometry (DXA/DEXA) technology intended for preclinical studies. It offers a comprehensive solution for assessing a wide range ...
OsteoSys’ iNSiGHT dual-energy X-ray absorptiometry (DXA) scanner (with a 25-second scan time) can successfully deliver reproducible data for measuring global and local alterations in rat and mouse ...
Socioeconomic deprivation is associated with increased odds of fragility fractures, osteoporosis, and higher abdominal and femoral fat levels.
BIDMC Investigator Contributes To FDA Approval of New and Better Way To Test Osteoporosis Treatments
BIDMC investigator Mary Bouxsein helped secure FDA approval of bone density imaging as a faster endpoint for osteoporosis ...
10d
FNIH Announces FDA Qualification of First Surrogate Endpoint for Use in Osteoporosis Clinical Trials
FDA has qualified the first surrogate endpoint for bone fractures in anti-osteoporosis drug trials for at-risk ...
The FDA greenlights treatment-related changes in bone mineral density as a surrogate endpoint in anti-osteoporosis drug trials in postmenopausal women.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback